Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03495882 | Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) | PHASE1 | COMPLETED | 154 | — | — | Dec 18, 2017 | Jul 15, 2022 | Jul 5, 2023 | 47 | United States, Australia +7 |
per RECIST 1.1
| Arm | Type | Description |
|---|---|---|
| AGEN1884 + AGEN2034 | EXPERIMENTAL | AGEN1884 in combination with AGEN2034 in subjects with Subjects with Metastatic or Locally Advanced Solid Tumors, and Expansion into Select Solid Tumors (cervical) |
| Name | Type | Description |
|---|---|---|
| AGEN1884 + AGEN2034 | DRUG | AGEN1884 + AGEN2034 according to protocol design |
Inclusion Criteria: To be eligible for participation in this trial the subject must: 1. Voluntarily agree to participate by giving written informed consent. (Participation in pharmacogenomics testing is optional.) 2. Be ≥18 years of age. 3. Diagnosis: 1. Phase 1: Male or female having a histol...